Strategic partnerships Arbor has active and growing collaboration momentum with regional and global health entities, including a DoH - Abu Dhabi MoU and a Sidra Qatar partnership, signaling open doors for co-development, licensing, or regional clinical trial programs.

Executive momentum Recent leadership changes and appointments, including a new Chief Scientific Officer and a new VP of Clinical Development for CNS, indicate a strategic shift and renewed focus on advancing programs that may benefit from external collaboration or sponsored research partnerships.

CNS focus A CNS-centric pipeline targeting ALS and general CNS genomic medicine presents opportunities for collaborations with neurology clinics, contract research organizations, and specialty pharma seeking CNS gene-editing outcomes, biomarkers, or access to first-in-class therapies.

Global outreach Ongoing international collaborations and global partners, including a potential licensing or joint development path with Chiesi and Abu Dhabi DoH, create avenues for regional commercialization, technology licensing, and multi-country clinical studies.

Financial readiness With substantial funding and a mid-sized revenue base, Arbor has the financial runway to pursue strategic partnerships, co-development deals, and milestone-driven collaborations that align with its gene-editing platform and clinical programs.